Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Pederzoli F, Raffo M, Pakula H, Ravera F, Nuzzo PV, Loda M. "Stromal cells in prostate cancer pathobiology: friends or foes?". Br J Cancer. 2023;128(6):930-939.

Stein BD, Ferrarone JR, Gardner EE, Chang JW, Wu D, Hollstein PE, et al. LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma. Cancer Discov. 2023;13(4):1002-1025.

Beg S, Zanettini C, Queiroz L, Marchionni L, Alperstein SA, Siddiqui MT. Optimal fluid volume for detecting malignancy in serous effusions: a single institution experience. J Am Soc Cytopathol. 2023;12(6):415-422.

Adegbite BO, Abramson MH, Gutgarts V, Musteata FM, Chauhan K, Muwonge AN, et al. Patient-Specific Pharmacokinetics and Dasatinib Nephrotoxicity. Clin J Am Soc Nephrol. 2023;18(9):1175-1185.

Hissong E, Zhao L, Shi J. Clinicopathologic and Molecular Features of Pancreatic Ductal Adenocarcinomas Harboring Alterations in COMPASS-like Complex Genes. Arch Pathol Lab Med. 2023;147(9):1050-1059.

Melis M, Trasino SE, Tang X-, Rappa A, Zhang T, Qin L, et al. Retinoic Acid Receptor β Loss in Hepatocytes Increases Steatosis and Elevates the Integrated Stress Response in Alcohol-Associated Liver Disease. Int J Mol Sci. 2023;24(15).

Nassar AH, Alaiwi SA, Baca SC, Adib E, Corona RI, Seo J-, et al. Epigenomic charting and functional annotation of risk loci in renal cell carcinoma. Nat Commun. 2023;14(1):346.

Hahn NM, O'Donnell MA, Efstathiou JA, Zahurak M, Rosner GL, Smith J, et al. A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study. Eur Urol. 2023;83(6):486-494.

Callum J, Bégin P, Jamula E, Liu Y, Kron AT, Auclair M-, et al. Lessons learned from the CONCOR-1 trial. Transfus Med. 2023;33(1):21-25.

Marinoff AE, Spurr LF, Fong C, Li YY, Forrest SJ, Ward A, et al. Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma. JCO Precis Oncol. 2023;7:e2200334.